Report

TABLE OF CONTENTS
1 INTRODUCTION 96
1.1 OBJECTIVES OF THE STUDY 96
1.2 MARKET DEFINITION 96
1.3 OVERVIEW OF GLOBAL CANCER PHOTODYNAMIC THERAPY MARKET 96
1.4 LIMITATIONS 99
1.5 MARKETS COVERED 99
2 MARKET SEGMENTATION 104
2.1 MARKETS COVERED 104
2.2 GEOGRAPHICAL SCOPE 105
2.3 YEARS CONSIDERED FOR THE STUDY 106
2.4 CURRENCY AND PRICING 106
2.5 DBMR TRIPOD DATA VALIDATION MODEL 107
2.6 MULTIVARIATE MODELLING 110
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 111
2.8 DBMR MARKET POSITION GRID 113
2.9 MARKET END USER COVERAGE GRID 114
2.10 SECONDARY SOURCES 115
2.11 ASSUMPTIONS 116
3 EXECUTIVE SUMMARY 117
4 PREMIUM INSIGHTS 123
4.1 PORTER'S FIVE FORCES 125
4.2 PESTEL ANALYSIS 126
4.3 PRODUCTION CONSUMPTION ANALYSIS 127
4.3.1 INTRODUCTION 127
4.3.2 PRODUCTION SIDE ANALYSIS 127
4.3.2.1 PHOTOSENSITIZER MANUFACTURING 127
4.3.2.2 DEVICE MANUFACTURING 127
4.3.2.3 RESEARCH AND INNOVATION 127
4.3.3 CONSUMPTION SIDE ANALYSIS 127
4.3.3.1 CLINICAL APPLICATION 127
4.3.3.2 TREATMENT VOLUMES AND TRENDS 127
4.3.3.3 DOSAGE AND PROTOCOLS 127
4.3.4 PRODUCTION-CONSUMPTION DYNAMICS 128
4.3.4.1 SUPPLY CONSTRAINTS 128
4.3.4.2 REGIONAL OVERVIEW 128
4.3.4.3 FUTURE OUTLOOK 128
4.3.5 CONCLUSION 128
4.4 COST ANALYSIS BREAKDOWN 129
4.4.1 INTRODUCTION 129
4.4.2 DIRECT MEDICAL COSTS 129
4.4.2.1 COST OF PHOTOSENSITIZERS 129
4.4.2.2 LIGHT DELIVERY SYSTEMS 129
4.4.2.3 HEALTHCARE FACILITY CHARGES 129
4.4.3 INDIRECT COSTS 129
4.4.3.1 PATIENT-RELATED EXPENSES 129
4.4.3.2 POST-TREATMENT MONITORING 129
4.4.4 COMPARATIVE COST-EFFECTIVENESS 129
4.4.5 REIMBURSEMENT AND INSURANCE IMPACT 129
4.4.6 REGIONAL COST VARIATIONS 130
4.4.7 FUTURE COST TRENDS AND REDUCTION STRATEGIES 130
4.4.7.1 TECHNOLOGICAL ADVANCEMENTS 130
4.4.7.2 HEALTHCARE EFFICIENCY INITIATIVES 130
4.4.8 CONCLUSION 130
4.5 TECHNOLOGICAL ADVANCEMENTS 131
4.5.1 INTRODUCTION 131
4.5.2 NEXT-GENERATION PHOTOSENSITIZERS 131
4.5.3 ADVANCEMENTS IN LIGHT DELIVERY SYSTEMS 131
4.5.4 NANOTECHNOLOGY-ENABLED DELIVERY 131
4.5.5 COMBINATION THERAPIES AND IMMUNOMODULATION 131
4.5.6 DIGITAL INTEGRATION AND TREATMENT PLANNING 132
4.5.7 RECENT TRENDS AND OUTLOOK 132
4.5.8 CONCLUSION 132
4.6 VALUE CHAIN ANALYSIS 133
4.6.1 INTRODUCTION 133
4.6.2 RESEARCH & DEVELOPMENT 133
4.6.2.1 DISCOVERY OF PHOTOSENSITIZERS 133
4.6.2.2 DEVELOPMENT OF LIGHT DELIVERY SYSTEMS 133
4.6.2.3 CLINICAL TRIALS AND REGULATORY APPROVALS 133
4.6.3 MANUFACTURING 133
4.6.3.1 PRODUCTION OF PHOTOSENSITIZERS 133
4.6.3.2 FABRICATION OF LIGHT DELIVERY DEVICES 133
4.6.4 DISTRIBUTION & LOGISTICS 134
4.6.4.1 SUPPLY CHAIN MANAGEMENT 134
4.6.4.2 INTERNATIONAL TRADE AND MARKET ACCESS 134
4.6.5 CLINICAL APPLICATION 134
4.6.5.1 INTEGRATION INTO TREATMENT PROTOCOLS 134
4.6.5.2 TRAINING AND EDUCATION 134
4.6.6 POST-TREATMENT MONITORING & SUPPORT 134
4.6.6.1 FOLLOW-UP CARE 134
4.6.6.2 PATIENT SUPPORT SERVICES 134
4.6.7 TECHNOLOGICAL ADVANCEMENTS INFLUENCING THE PDT VALUE CHAIN 134
4.6.7.1 NANOTECHNOLOGY IN PDT 134
4.6.7.2 ARTIFICIAL INTELLIGENCE AND IMAGING 134
4.6.7.3 PERSONALIZED MEDICINE 135
4.6.8 CONCLUSION 135
4.7 VENDOR SELECTION CRITERIA 136
4.7.1 INTRODUCTION 136
4.7.2 CORE SELECTION CRITERIA 136
4.7.2.1 REGULATORY COMPLIANCE 136
4.7.2.2 CLINICAL EVIDENCE AND RESEARCH SUPPORT 136
4.7.2.3 TECHNICAL PERFORMANCE AND DEVICE COMPATIBILITY 136
4.7.2.4 QUALITY MANAGEMENT AND MANUFACTURING STANDARDS 136
4.7.2.5 SERVICE, TRAINING, AND AFTER-SALES SUPPORT 136
4.7.2.6 SUPPLY CHAIN RELIABILITY 136
4.7.3 RECENT TRENDS IN VENDOR SELECTION 137
4.7.4 RISK FACTORS AND VULNERABILITIES 137
4.7.5 KEY PERFORMANCE INDICATORS 137
4.7.6 STRATEGIC RECOMMENDATIONS 137
4.7.7 CONCLUSION 137
4.8 PATENT ANALYSIS 138
4.8.1 PATENT QUALITY AND STRENGTH 138
4.8.2 PATENT FAMILIES 139
4.8.3 LICENSING AND COLLABORATIONS 139
4.8.4 REGIONAL PATENT LANDSCAPE 140
4.8.5 IP STRATEGY AND MANAGEMENT 142
4.9 SUPPLY CHAIN ANALYSIS 143
4.9.1 OVERVIEW 143
4.9.2 LOGISTIC COST SCENARIO 143
4.9.3 IMPORTANCE OF LOGISTICS SERVICE PROVIDERS 143
4.9.4 CONCLUSION 144
4.10 INDUSTRY ECOSYSTEM ANALYSIS 145
4.10.1 INTRODUCTION 145
4.10.2 ECOSYSTEM ARCHITECTURE - KEY ACTORS AND ROLES 145
4.10.2.1 CORE TECHNOLOGY PROVIDERS 145
4.10.2.2 ENABLING INSTITUTIONS 145
4.10.3 VALUE CHAIN AND FUNCTIONAL FLOWS 145
4.10.3.1 RESEARCH AND DISCOVERY 145
4.10.3.2 CLINICAL DEVELOPMENT AND REGULATORY VALIDATION 145
4.10.3.3 MANUFACTURING AND QUALITY ASSURANCE 146
4.10.3.4 DISTRIBUTION, PROCUREMENT AND CLINICAL ADOPTION 146
4.10.4 MARKET ENABLERS AND INFRASTRUCTURE 146
4.10.4.1 SCIENTIFIC AND REGULATORY ENABLERS 146
4.10.4.2 REIMBURSEMENT AND HEALTH-ECONOMICS INFRASTRUCTURE 146
4.10.4.3 MANUFACTURING AND SUPPLY-CHAIN CAPACITY 146
4.10.5 INTERDEPENDENCIES AND STRATEGIC PARTNERSHIPS 146
4.10.5.1 ACADEMIA-INDUSTRY TECHNOLOGY TRANSFER 146
4.10.5.2 VERTICAL INTEGRATION AND CONTRACT MANUFACTURING 146
4.10.5.3 CLINICAL NETWORKS AND KOL ECOSYSTEMS 146
4.10.6 RISKS, CONSTRAINTS AND SYSTEMIC VULNERABILITIES 147
4.10.6.1 REGULATORY COMPLEXITY FOR COMBINED PRODUCTS 147
4.10.6.2 SUPPLY-CHAIN CONCENTRATION AND MATERIAL RISK 147
4.10.6.3 EVIDENCE AND REIMBURSEMENT UNCERTAINTY 147
4.10.6.4 CLINICAL OPERATIONAL BARRIERS 147
4.10.7 STRATEGIC IMPLICATIONS AND RECOMMENDATIONS 147
4.10.8 OUTLOOK - EVOLUTION OF THE ECOSYSTEM 147
4.10.9 CONCLUSION 148
4.11 INNOVATION TRACKER AND STRATEGIC ANALYSIS 149
4.11.1 INTRODUCTION 149
4.11.2 RECENT TECHNOLOGICAL INNOVATIONS 149
4.11.2.1 ADVANCED PHOTOSENSITIZERS 149
4.11.2.2 OXYGEN-SELF-SUFFICIENT PLATFORMS 149
4.11.2.3 ALTERNATIVE ACTIVATION MODALITIES 149
4.11.2.4 SMART NANOPLATFORMS 149
4.11.2.5 NOVEL CHEMICAL STRUCTURES 149
4.11.3 STRATEGIC INNOVATIONS IN DELIVERY SYSTEMS 149
4.11.3.1 LIGHT DELIVERY DEVICES 149
4.11.3.2 COMBINATION THERAPIES 149
4.11.3.3 IMAGING INTEGRATION 149
4.11.4 KEY CHALLENGES 150
4.11.5 STRATEGIC THEMES 150
4.11.6 STRATEGIC IMPLICATIONS FOR MARKET PLAYERS 150
4.11.7 RECOMMENDATIONS 150
4.11.8 OUTLOOK AND STRATEGIC RISKS 150
4.11.9 CONCLUSION 150
4.12 PRICING ANALYSIS 151
4.12.1 INTRODUCTION 151
4.12.2 COMPONENTS OF THE TOTAL TREATMENT PRICE 151
4.12.2.1 PHOTOSENSITIZING AGENT (DRUG) COSTS 151
4.12.2.2 DEVICE CAPITAL AND MAINTENANCE COST 151
4.12.2.3 CONSUMABLES AND PROCEDURAL OVERHEAD 151
4.12.2.4 INDIRECT AND DOWNSTREAM COSTS 151
4.12.3 PRICING MODELS AND APPROACHES 151
4.12.3.1 COST-PLUS AND MARKUP MODELS 151
4.12.3.2 VALUE-BASED AND OUTCOMES-LINKED PRICING 151
4.12.3.3 BUNDLED PAYMENTS AND PROCEDURAL TARIFFS 152
4.12.3.4 SUBSCRIPTION AND MANAGED-SERVICE MODELS FOR DEVICES 152
4.12.4 REIMBURSEMENT LANDSCAPE 152
4.12.4.1 UNITED STATES: MEDICARE AND COMMERCIAL PAYERS 152
4.12.4.2 EUROPE AND OTHER HIGH-INCOME MARKETS 152
4.12.4.3 EMERGING MARKETS AND OUT-OF-POCKET DYNAMICS 152
4.12.5 REGIONAL PRICE DIFFERENTIALS AND DRIVERS 152
4.12.5.1 MANUFACTURING FOOTPRINT AND SUPPLY-CHAIN EFFECTS 152
4.12.5.2 REGULATORY BURDEN AND MARKET ACCESS TIMELINES 152
4.12.5.3 CLINICAL PRACTICE PATTERNS AND REIMBURSEMENT POLICY 152
4.12.6 PRICE SENSITIVITY, ACCESS, AND EQUITY 153
4.12.6.1 PRICE ELASTICITY IN HOSPITAL PROCUREMENT 153
4.12.6.2 PATIENT ACCESS AND SOCIOECONOMIC BARRIERS 153
4.12.7 COMPETITIVE & STRATEGIC PRICING IMPLICATIONS 153
4.12.7.1 DIFFERENTIATION-BASED PREMIUM PRICING 153
4.12.7.2 PENETRATION PRICING AND VOLUME STRATEGIES 153
4.12.7.3 MANAGED ENTRY AGREEMENTS AND OUTCOMES GUARANTEES 153
4.12.8 RECOMMENDATIONS FOR STAKEHOLDERS 153
4.12.8.1 FOR MANUFACTURERS 153
4.12.8.2 FOR PROVIDERS AND HOSPITAL SYSTEMS 153
4.12.8.3 FOR PAYERS AND POLICYMAKERS 153
4.12.9 RISKS, UNCERTAINTIES, AND FUTURE PRICE PRESSURES 154
4.12.10 CONCLUSION 154
5 TARIFFS & IMPACT ON THE MARKET 155
5.1 INTRODUCTION 155
5.2 TARIFF LANDSCAPE RELEVANT TO PDT PRODUCTS 155
5.2.1 CATEGORIES OF TRADE EXPOSURE 155
5.2.2 RECENT AND EMERGING TARIFF MEASURES OF CONSEQUENCE 155
5.3 DIRECT COST IMPACTS 155
5.3.1 INCREASED LANDED COSTS AND MARGIN COMPRESSION 155
5.3.2 PRICE VOLATILITY AND PROCUREMENT BUDGETING 155
5.4 SUPPLY-CHAIN & MANUFACTURING IMPLICATIONS 156
5.4.1 SUPPLIER DIVERSIFICATION AND RESHORING INCENTIVES 156
5.4.2 SOURCING OF HIGH-VALUE NANOMATERIALS AND COMPONENTS 156
5.4.3 REGULATORY AND QUALIFICATION COSTS FOR NEW SUPPLIERS 156
5.5 CLINICAL ACCESS, PRICING & REIMBURSEMENT EFFECTS 156
5.5.1 ACCESS RISK FOR PATIENTS AND PROVIDERS 156
5.5.2 REIMBURSEMENT PRESSURE AND HEALTH-ECONOMIC ASSESSMENTS 156
5.6 R&D, INNOVATION & COMPETITIVE IMPLICATIONS 156
5.6.1 DISRUPTION OF RESEARCH SUPPLIES AND COLLABORATION FLOWS 156
5.6.2 STRATEGIC REPOSITIONING AND COMPETITIVE ADVANTAGE 156
5.7 POLICY, COMPLIANCE & REGULATORY CONSIDERATIONS 157
5.7.1 USE OF WTO AND PREFERENTIAL TRADE RULES 157
5.7.2 TARIFF MITIGATION TOOLS AND ADVOCACY 157
5.8 RECOMMENDATIONS FOR STAKEHOLDERS 157
5.9 CONCLUSION 157
6 REGULATION COVERAGE 158
6.1 PRODUCT CODES 158
6.1.1 CERTIFIED STANDARDS 158
6.1.2 SAFETY STANDARDS 159
6.1.3 MATERIAL HANDLING & STORAGE 159
6.1.4 TRANSPORT & PRECAUTIONS 159
6.1.5 HAZARD IDENTIFICATION 159
6.1.6 CONCLUSION 160
7 MARKET OVERVIEW 161
7.1 DRIVERS 163
7.1.1 INCREASING PREVALENCE OF CANCER 163
7.1.2 GROWING PREFERENCE FOR MINIMALLY INVASIVE THERAPIES 164
7.1.3 TECHNOLOGICAL ADVANCEMENTS IN PHOTOSENSITIZERS AND DEVICES 165
7.1.4 EXPANDING RESEARCH AND CLINICAL DEVELOPMENT PIPELINE 166
7.2 RESTRAINTS 167
7.2.1 LIMITED DEPTH OF LIGHT PENETRATION 167
7.2.2 HIGH COST OF TREATMENT 168
7.3 OPPORTUNITIES 169
7.3.1 INTEGRATION WITH OTHER CANCER THERAPIES 169
7.3.2 DEVELOPMENT OF NOVEL PHOTOSENSITIZERS 170
7.3.3 M&A AND PARTNERSHIPS WITH ONCOLOGY DEVICE/LASER FIRMS AND PHARMA 171
7.4 CHALLENGES 172
7.4.1 TUMOR HYPOXIA AS A BIOLOGICAL BARRIER TO PHOTODYNAMIC THERAPY EFFICACY 172
7.4.2 COMPETITION FROM ALTERNATIVE TREATMENTS 173
8 GLOBAL CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE 174
8.1 OVERVIEW 175
8.2 PHOTOSENSITIZER DRUGS 178
8.3 PHOTODYNAMIC THERAPY DEVICES 180
9 GLOBAL CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION 182
9.1 OVERVIEW 183
9.2 SKIN & CUTANEOUS ONCOLOGY 186
9.3 HEAD & NECK 187
9.4 ESOPHAGAL 189
9.5 LUNG 190
9.6 BLADDER 191
9.7 CERVICAL 193
9.8 PROSTATE 194
10 GLOBAL CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY 195
10.1 OVERVIEW 196
10.2 STANDALONE THERAPY 199
10.3 ADJUNCTIVE THERAPY 200
10.4 PALLIATION THERAPY 200
10.5 OTHERS 201
11 GLOBAL CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE 202
11.1 OVERVIEW 203
11.2 EXTERNAL BEAM 206
11.3 INTRACAVITARY (ENDOSCOPIC) DELIVERY 206
11.4 INTERSTITIAL (INTERNAL) DELIVERY 207
11.5 OTHERS 207
12 GLOBAL CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE 208
12.1 OVERVIEW 209
12.2 EARLY-STAGE CANCER 212
12.3 LATE-STAGE CANCER 212
13 GLOBAL CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS 213
13.1 OVERVIEW 214
13.2 GERIATRIC 217
13.3 ADULTS 217
13.4 PEDIATRIC 218
14 GLOBAL CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER 219
14.1 OVERVIEW 220
14.2 HOSPITALS 223
14.3 DERMATOLOGY & SKIN-CANCER CLINICS 224
14.4 AMBULATORY SURGICAL CENTERS (ASCS) 225
14.5 ACADEMIC & RESEARCH INSTITUTES 225
14.6 OTHERS 226
15 GLOBAL CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL 227
15.1 OVERVIEW 228
15.2 DIRECT TENDER 231
15.3 THIRD PARTY DISTRIBUTORS 231
15.4 ONLINE 232
15.5 OTHERS 232
16 GLOBAL CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION 233
16.1 OVERVIEW 234
16.2 NORTH AMERICA 238
16.2.1 U.S. 249
16.2.2 CANADA 259
16.2.3 MEXICO 268
16.3 EUROPE 277
16.3.1 GERMANY 287
16.3.2 U.K. 296
16.3.3 FRANCE 305
16.3.4 ITALY 314
16.3.5 SPAIN 323
16.3.6 RUSSIA 332
16.3.7 TURKEY 341
16.3.8 SWITZERLAND 350
16.3.9 BELGIUM 359
16.3.10 NETHERLANDS 368
16.3.11 SWEDEN 377
16.3.12 DENMARK 386
16.3.13 NORWAY 395
16.3.14 FINLAND 404
16.3.15 REST OF EUROPE 413
16.4 ASIA-PACIFIC 414
16.4.1 CHINA 424
16.4.2 JAPAN 433
16.4.3 SOUTH KOREA 442
16.4.4 AUSTRAILA 451
16.4.5 TAIWAN 460
16.4.6 INDIA 469
16.4.7 INDONESIA 478
16.4.8 HONG KONG 487
16.4.9 NEW ZEALAND 496
16.4.10 SINGAPORE 505
16.4.11 PHILIPPINES 514
16.4.12 THAILAND 523
16.4.13 MALAYSIA 532
16.4.14 REST OF ASIA-PACIFIC 541
16.5 MIDDLE EAST AND AFRICA 542
16.5.1 SOUTH AFRICA 552
16.5.2 SAUDI ARABIA 561
16.5.3 EGYPT 570
16.5.4 U.A.E 579
16.5.5 ISRAEL 588
16.5.6 BAHRAIN 597
16.5.7 KUWAIT 606
16.5.8 OMAN 615
16.5.9 QATAR 624
16.5.10 REST OF MIDDLE EAST AND AFRICA 633
16.6 SOUTH AMERICA 634
16.6.1 BRAZIL 644
16.6.2 ARGENTINA 653
16.6.3 COLOMBIA 662
16.6.4 CHILE 671
16.6.5 PERU 680
16.6.6 VENEZUELA 689
16.6.7 ECUADOR 698
16.6.8 URUGUAY 707
16.6.9 PARAGUAY 716
16.6.10 BOLIVIA 725
16.6.11 REST OF SOUTH AMERICA 734
17 GLOBAL CANCER PHOTODYNAMIC THERAPY MARKET: COMPANY LANDSCAPE 735
17.1 COMPANY SHARE ANALYSIS: GLOBAL 735
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 736
17.3 COMPANY SHARE ANALYSIS: EUROPE 737
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 738
18 SWOT ANALYSIS 739
19 COMPANY PROFILE 740
19.1 NOVERTIS AG 740
19.1.1 COMPANY SNAPSHOT 740
19.1.2 REVENUE ANALYSIS 740
19.1.3 COMPANY SHARE ANALYSIS 741
19.1.4 PRODUCT PORTFOLIO 741
19.1.5 RECENT DEVELOPMENT 741
19.2 GALDERMA S. A. 742
19.2.1 COMPANY SNAPSHOT 742
19.2.2 REVENUE ANALYSIS 743
19.2.3 COMPANY SHARE ANALYSIS 743
19.2.4 PRODUCT PORTFOLIO 744
19.2.5 RECENT DEVELOPMENTS 744
19.3 PHOTOCURE 745
19.3.1 COMPANY SNAPSHOT 745
19.3.2 REVENUE ANALYSIS 745
19.3.3 COMPANY SHARE ANALYSIS 746
19.3.4 PRODUCT PORTFOLIO 746
19.3.5 RECENT DEVELOPMENT 747
19.4 ADVANZ PHARMA CORP. 748
19.4.1 COMPANY SNAPSHOT 748
19.4.2 COMPANY SHARE ANALYSIS 748
19.4.3 PRODUCT PORTFOLIO 749
19.4.4 RECENT DEVELOPMENT 749
19.5 AMERISOURCE BERGEN CORPORATION 750
19.5.1 COMPANY SNAPSHOT 750
19.5.2 REVENUE ANALYSIS 750
19.5.3 COMPANY SHARE ANALYSIS 751
19.5.4 PRODUCT PORTFOLIO 751
19.5.5 RECENT DEVELOPMENT 752
19.6 BIOFRONTERA AG 753
19.6.1 COMPANY SNAPSHOT 753
19.6.2 REVENUE ANALYSIS 753
19.6.3 PRODUCT PORTFOLIO 754
19.6.4 RECENT DEVELOPMENTS 754
19.7 BIOLITEC HOLDING GMBH & CO KG 755
19.7.1 COMPANY SNAPSHOT 755
19.7.2 PRODUCT PORTFOLIO 755
19.7.3 RECENT DEVELOPMENT 755
19.8 CARDINAL HEALTH 756
19.8.1 COMPANY SNAPSHOT 756
19.8.2 REVENUE ANALYSIS 756
19.8.3 PRODUCT PORTFOLIO 757
19.8.4 RECENT DEVELOPMENT 758
19.9 HEMERION THERAPEUTICS 759
19.9.1 COMPANY SNAPSHOT 759
19.9.2 PRODUCT PORTFOLIO 759
19.9.3 RECENT DEVELOPMENTS 759
19.10 IMPACT BIOTECH 760
19.10.1 COMPANY SNAPSHOT 760
19.10.2 PRODUCT PORTFOLIO 760
19.10.3 RECENT DEVELOPMENTS 760
19.11 INOVA 761
19.11.1 COMPANY SNAPSHOT 761
19.11.2 PRODUCT PORTFOLIO 761
19.11.3 RECENT DEVELOPMENT 761
19.12 LUMIBIRD 762
19.12.1 COMPANY SNAPSHOT 762
19.12.2 REVENUE ANALYSIS 762
19.12.3 PRODUCT PORTFOLIO 763
19.12.4 RECENT DEVELOPMENT 763
19.13 LUZITIN 764
19.13.1 COMPANY SNAPSHOT 764
19.13.2 PRODUCT PORTFOLIO 764
19.13.3 RECENT DEVELOPMENT 764
19.14 MCKESSON 765
19.14.1 COMPANY SNAPSHOT 765
19.14.2 REVENUE ANALYSIS 765
19.14.3 PRODUCT PORTFOLIO 766
19.14.4 RECENT DEVELOPMENTS 766
19.15 MODULIGHT CORPORATION 767
19.15.1 COMPANY SNAPSHOT 767
19.15.2 REVENUE ANALYSIS 767
19.15.3 PRODUCT PORTFOLIO 768
19.15.4 RECENT DEVELOPMENT 768
19.16 ONCOLUX INC (FORMERLY LUMEDA INC.) 769
19.16.1 COMPANY SNAPSHOT 769
19.16.2 PRODUCT PORTFOLIO 769
19.16.3 RECENT DEVELOPMENT 769
19.17 SUN PHARMACEUTICAL INDUSTRIES LTD 770
19.17.1 COMPANY SNAPSHOT 770
19.17.2 REVENUE ANALYSIS 771
19.17.3 PRODUCT PORTFOLIO 771
19.17.4 RECENT DEVELOPMENT 772
19.18 THERALASE TECHNOLOGIES INC. 773
19.18.1 COMPANY SNAPSHOT 773
19.18.2 REVENUE ANALYSIS 773
19.18.3 PRODUCT PORTFOLIO 774
19.18.4 RECENT DEVELOPMENT 774
20 QUESTIONNAIRE 775
21 RELATED REPORTS 778
?